|
|
|
|
|
|
|
|
abstract/open access
Abstract
Objectives: Patients with mucinous ovarian carcinoma
(MOC) generally have a favorable prognosis, although in advanced stage,
prognosis is significantly worse compared to patients with serous
ovarian carcinomas (SOCs). This might be due to the difficulties in
distinguishing MOC from metastatic tumors. In the current study, we
investigate prognosis of MOC compared to other types of ovarian cancer
and to synchronous metastases to the ovary (sMO).
Materials and Methods: Age, laterality, International
Federation of Gynecology and Obstetrics stage, tumor grade, treatment,
and survival were extracted from the Eindhoven Cancer registry for all
patients diagnosed with ovarian carcinomas or sMO between 1990 and 2012.
Five-year survival analysis and Cox proportional hazards analysis were
conducted.
Results:
A total of 3556 patients with primary ovarian carcinoma (of which 474
mucinous) and 289 with sMO were identified. In advanced stage, 5-year
survival of patients with MOC was comparable to survival of patients
with sMO (11% vs 11%, P = 0.32) and decreased compared to patients with SOC (26%, P < 0.01). For MOC, there was no clinically significant effect on 5-year survival of either debulking (12% vs 8%, P < 0.01) or chemotherapy (12% vs 10%, P = 0.02).
Conclusions: Patients with advanced stage MOC have a
worse prognosis than advanced stage SOC. Survival is almost identical to
that of patients with sMO. Effects of chemotherapy and debulking are
limited in patients with MOC, which may be explained by suboptimal
treatment due to the admixture of metastases in advanced stage MOC.
Methods to differentiate between primary MOC and metastatic disease are
needed to provide optimal treatment and insight in prognosis.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.